These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 26966363)
1. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. de Biase S; Valente M; Gigli GL Neuropsychiatr Dis Treat; 2016; 12():417-25. PubMed ID: 26966363 [TBL] [Abstract][Full Text] [Related]
2. Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. de Biase S; Merlino G; Valente M; Gigli GL Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1035-45. PubMed ID: 27310338 [TBL] [Abstract][Full Text] [Related]
3. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R; Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442 [TBL] [Abstract][Full Text] [Related]
4. Opioids for restless legs syndrome. de Oliveira CO; Carvalho LB; Carlos K; Conti C; de Oliveira MM; Prado LB; Prado GF Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006941. PubMed ID: 27355187 [TBL] [Abstract][Full Text] [Related]
5. Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. Frampton JE CNS Drugs; 2015 Jun; 29(6):511-8. PubMed ID: 26135898 [TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for restless legs syndrome. Ferini-Strambi L; Marelli S Expert Opin Pharmacother; 2014 Jun; 15(8):1127-38. PubMed ID: 24745717 [TBL] [Abstract][Full Text] [Related]
10. Advancing synthetic therapies for the treatment of restless legs syndrome. de Biase S; Pellitteri G; Gigli GL; Valente M Expert Opin Pharmacother; 2019 Nov; 20(16):1971-1980. PubMed ID: 31424287 [No Abstract] [Full Text] [Related]
11. Restless legs syndrome: pathophysiology and modern management. Nagandla K; De S Postgrad Med J; 2013 Jul; 89(1053):402-10. PubMed ID: 23524988 [TBL] [Abstract][Full Text] [Related]
12. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171 [TBL] [Abstract][Full Text] [Related]
13. Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update. Salminen AV; Winkelmann J Curr Treat Options Neurol; 2018 Nov; 20(12):55. PubMed ID: 30411165 [TBL] [Abstract][Full Text] [Related]
14. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome. Sun Y; van Valkenhoef G; Morel T Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588 [TBL] [Abstract][Full Text] [Related]
15. Restless Legs Syndrome: Contemporary Diagnosis and Treatment. Gossard TR; Trotti LM; Videnovic A; St Louis EK Neurotherapeutics; 2021 Jan; 18(1):140-155. PubMed ID: 33880737 [TBL] [Abstract][Full Text] [Related]
17. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465 [TBL] [Abstract][Full Text] [Related]
18. Restless legs syndrome-current therapies and management of augmentation. Trenkwalder C; Winkelmann J; Inoue Y; Paulus W Nat Rev Neurol; 2015 Aug; 11(8):434-45. PubMed ID: 26215616 [TBL] [Abstract][Full Text] [Related]
19. Investigational approaches to therapies for restless legs syndrome. de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL Expert Opin Investig Drugs; 2014 Jun; 23(6):847-56. PubMed ID: 24708072 [TBL] [Abstract][Full Text] [Related]